MENU
+Compare
ONCO
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$0.53
Change
+$0.02 (+3.92%)
Capitalization
4.4M

ONCO Onconetix Inc Forecast, Technical & Fundamental Analysis

Industry Biotechnology
ONCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ONCO with price predictions
Jan 14, 2025

ONCO in -15.58% downward trend, falling for three consecutive days on January 10, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONCO declined for three days, in of 243 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

ONCO broke above its upper Bollinger Band on December 31, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ONCO entered a downward trend on December 30, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ONCO's RSI Oscillator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on December 30, 2024. You may want to consider a long position or call options on ONCO as a result. In of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCO advanced for three days, in of 95 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.130) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). ONCO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.205) is also within normal values, averaging (263.573).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ONCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ONCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ONCO is expected to report earnings to rise 10.53% to -20 cents per share on March 07

Onconetix Inc ONCO Stock Earnings Reports
Q4'23
Est.
$-0.21
Q3'23
Est.
$-0.19
Q2'23
Missed
by $0.06
Q1'23
Beat
by $0.02
Q4'22
Beat
by $0.05
The last earnings report on November 09 showed earnings per share of -18 cents, meeting the estimate of -18 cents. With 383.82K shares outstanding, the current market capitalization sits at 4.40M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
201 East Fifth Street
Phone
+1 513 620-4101
Employees
12
Web
https://www.onconetix.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

ONCO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ONCO has been loosely correlated with OPORF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ONCO jumps, then OPORF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ONCO
1D Price
Change %
ONCO100%
+3.37%
OPORF - ONCO
47%
Loosely correlated
N/A
INO - ONCO
43%
Loosely correlated
+8.90%
PCSA - ONCO
34%
Loosely correlated
-6.59%
NOXOF - ONCO
33%
Loosely correlated
N/A
EVAX - ONCO
30%
Poorly correlated
-8.04%
More